# Bridging Innovations QIAGENs Strides in Revamping Cancer Research and Global Diagnostics,

# Bridging Innovations QIAGENs Strides in Revamping Cancer Research and Global Diagnostics,

VENLO, Netherlands '' QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a front-runner in molecular testing solutions, is making strategic strides to enhance the landscape of oncology research and global health. Through notable partnerships, cutting-edge product launches, and upcoming technological advancements, this life sciences giant is steadfast in its mission to deliver groundbreaking solutions for cancer research, disease detection,…

QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions

Partnership designed to expand QIAGEN’s leadership in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for cancer research Combines QIAGEN’s global reach and automation expertise with ID Solutions’ assay developmen... L'articolo QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions è un contenuto originale di 01net.

With a firm commitment to leading innovation in the treatment of childhood cancer, HM Hospitals has launched, through the HM Hospitals Research Foundation, the Pediatric Oncology Research Unit at the Clara Campal Comprehensive Cancer Center (HM CIOCC). This new structure, which is a pioneer in the field of research within the Spanish private healthcare system, integrates for the first time a comprehensive R&D strategy focused on pediatric cancer…